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Introduction 
To date, there have been no studies which systematically examined if individuals with 
nonalcoholic fatty liver disease (NAFLD have an increased risk of drug induced liver injury. We 
conducted a study to test if the frequency of suspected DILI from prescription agents is higher in 
individuals with CLD suggestive of NAFLD.   
Methods  
The data for this IRB approved study were collected using the Indiana University Health 
Enterprise Data Warehouse. We identified three cohorts of individuals seen between January 1, 
2007 and December 31, 2017. CLD cohort suggestive of NAFLD (Suspected NAFLD 
cohort) had serum ALT > 45 U/L in ambulatory settings on at least two occasions occurring 6-
24 months apart in the absence of positive anti-HCV antibody, hepatitis B surface antigen, 
heavy alcohol consumption, hypotension, or DILI qualifying labs.  Control group 1 had ALT ≤ 
45 U/L on at least two occasions occurring 6-24 months apart whereas Control group 2 had 
ALT ≤ 31 U/L in men and ALT ≤ 19 U/L in women on at least two occasions occurring 6-24 
months apart. The three cohorts were mutually exclusive.   
  The three cohorts were further stratified according to exposure to one of ten select 
medications most frequently implicated to cause DILI in the United States. (1)  Exposed patients 
were prescribed one of these medications within one year of meeting eligibility for inclusion in 
the study cohorts described above.  Suspected DILI was defined based on previously published 
criteria (1, 2) with modifications: serum ALT > 200 U/L and/or serum alkaline phosphatase (Alk 
P) > 250 U/L and/or total bilirubin (T Bili) > 2.5 mg/dl on at least two consecutive occasions 
within three months after receiving one of ten candidate prescription medications, in the 
absence of positive hepatitis B surface antigen, positive HCV antibody, significant alcohol 
consumption, or hypotension. We assessed for the frequency of liver transplantation or death 
occurring within six months of the suspected DILI.   
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Results  
Four thousand eight hundred and thirty seven individuals in suspected NAFLD cohort, 
61,355 individuals in control group 1, and 47,869 individuals in control group 2 received a 
prescription for one of ten candidate medications. Their selected characteristics are shown in 
Table 1. The mean and median (range) baseline ALT levels in the suspected NAFLD cohort 
were 87 U/L and 73 (46-193) IU/L for the first value and 69 U/L and 58 (46-190) U/L for the 
second value. The frequency of prescriptions for various medications was generally consistent 
across these study groups, with cefazolin being the most and isoniazid being the least 
commonly prescribed medications. The frequency of suspected DILI in 4,837 individuals in 
suspected NAFLD cohort was 0.8% (40 out of 4,837) and it was significantly higher than in 
control group 1 (126 out of 61,355 [0.2%], OR: 4.0, 95% CI: 2.8-5.8, p<0.001) and control group 
2 (96 out 47,869 [0.2%], (OR: 4.17, 95% CI: 2.9-6.0), p<0.001) (Table 1).  The mean (s.d.) ALT, 
Alk P, and total bilirubin levels of suspected DILI cases were 191 ± 127 U/L, 197 ± 144 U/L, and 
2.25 ± 3.4 mg/dL in the suspected NAFLD group, 107 ± 147.5 U/L, 251 ± 170 U/L and 1.98 ± 
2.9 mg/dL in control group 1, and 102 ± 156 U/L, 251 ± 179 U/L, and 1.76 ± 1.42 mg/dL in 
control group, respectively. The frequency of death or liver transplant within 6 months of 
suspected DILI was 25% in the CLD cohort (10 out of 40) and it was numerically but not 
statistically higher than in either control group 1 (21 out of 126 [16.6%], p=0.2) or control group 
2 (13 out of 96 [13.5%], p=0.1).  (Table 1) 
Discussion 
This pharmaco-epidemiological study suggests that individuals with underlying chronic 
liver disease suggestive of NAFLD may be at higher risk for developing suspected DILI from 
prescription medications which are commonly implicated for causing DILI in the United States.     
An important limitation of our study is that we defined the presence of chronic liver 
disease and suspected DILI utilizing surrogate criteria. However, we established two carefully 
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constructed algorithms to define CLD and suspected DILI in this study.  Although we recognize 
that DILI can sometimes occur well beyond 3 months after initiating a culprit drug, we chose a 
12 week latency period to strengthen the temporal relationship between candidate medication 
exposure and the onset of the suspected DILI events.  Since we excluded individuals with 
hepatitis C, hepatitis B, or heavy alcohol consumption, our observations cannot be extended to 
individuals with CLD due to those etiologies. Our rationale behind excluding these etiologies 
was our intent to develop a CLD group that may mimic NAFLD.  Interestingly, the signal we 
observed is consistent with an earlier study which suggested that patients with NAFLD had four 
fold higher risk for DILI compared to chronic hepatitis C.(1)  In summary, these data suggest 
that individuals with suspected NAFLD may be at higher risk for suspected DILI.  More studies 
are needed to confirm our observations.  
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Table 1:  Selected Clinical Characteristics of Individuals who received one of 10 
candidate prescription medications¶ in 3 Study Cohorts 
Abbreviations:  BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine 
aminotransferase; Alk P: Alkaline phosphatase.   
¶ Ten candidate medications: Amoxicillin-clavulanate, isoniazid, nitrofurantoin, minocycline, trimethoprim-
sulfamethoxazole, ciprofloxacin levofloxacin, azithromycin, cefazolin, and diclofenac.    
 Exposed to one of 10 candidates medications  
 
Control 
group 1 
 
(n=61,355) 
 
Suspected 
NAFLD Cohort 
 
(n=4,837) 
 
Control 
group 2 
 
(n=47,869) 
 
Age (yr, mean ± SD) 
 
55.8 ± 18 50.6 ±14.7 56.7 ±18 
Females (%) 
 
65 48 60 
Ethnicity (Black/White) (%) 
 
11/87 8.6/90 12/87 
BMI (kg/m2, mean ± SD) 
 
31 ± 8.6 32.1 ± 8.7 30.4 ± 8.4 
AST at baseline (IU/L, mean ± SD) 
 
21.5 ± 11.5 56 ± 38 20 ± 11 
ALT at baseline (IU/L, mean ± SD) 
 
19 ± 8.2 69 ± 27 17 ± 5 
Alk P at baseline (IU/L, mean ± SD) 
 
74.5 ± 29 93 ± 41 73 ± 27 
Total bilirubin at baseline (mg/dL, 
mean ± SD)  
 
0.6 ± 0.5 0.7 ± 0.4 0.6 ± 0.34 
Presence of type 2 diabetesδ (%) 
 
24 34 24 
Presence of hypertensionδ (%) 
 
50 56 51 
 
Suspected DILI (%) 
 
0.2 0.8 0.2 
 
 
 
 
 
 
Death or transplantδ within 6 
months after suspected DILI 
Onset (%) 
16.6 25 13.5 
 
 
 
 
P<0.001 P <0.001 
P=0.2 P=0.1 
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δHypertension was identified based ICD10 like 'I1%' or ICD9 like '402%’, '403.%' , '404.%';   DM was 
identified based on ICD10 like 'E08%, 'E09%' , 'E10%' , 'E11%' or ICD9 like 'E250%'; Transplantation was 
identified using either ICD9 V42.7 or ICD10 Z94.4, or following procedures 471.35, 50.51, 50.59.  
